News
31 March 2020

EIB finances AM-Pharma's development of acute kidney injury treatment

In:
Infrastructure
Region:
Europe

The EIB and Utrecht-based AM-Pharma have signed a €24 million financing agreement. The funds will be used to accelerate the development of the clinical stage biopharmaceutical company’s recombinant alkaline phosphatase enzyme, which is used to treat acute kidney injury (AKI). The...

Exclusive subscriber content…

If you are a TXF subscriber, please login to continue reading

Login

Not yet a subscriber? Join us today to continue accessing content without any restrictions

View our subscription options

Or to request access to TXF Intelligence contact us

Request Access

You might also like


Perspective
11 March 2026

TXF Commodity Finance Perfect 10: Resilience is as important...

The word is out: TXF's Perfect 10 Commodity Finance Deals of the Year have been revealed. 2025 has shown that the best deals often come in smaller packages. This year's list...

Perspective
13 March 2026

TXF Export Finance Perfect 10: Bigger, bolder and greener

What TXF's 2025's award-winning export financings say about the state of the market in 2025. It was a year when all of the promise of the ECA-backed market - in size, ambition...